Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2020-10-20 Purchase |
2020-10-22 4:31 pm |
Aligos Therapeutics Inc. | ALGS | Novo Holdings A/S 10% Owner |
200,000 | $15 | $3,000,000 | 2,614,563 (Direct) |
View |
| 2020-10-20 Purchase |
2020-10-20 5:00 pm |
Aligos Therapeutics Inc. | ALGS | Woiwode Thomas Director |
200,000 | $15 | $3,000,000 | 862,444 (Indirect) |
View |
| 2020-10-20 Purchase |
2020-10-20 4:59 pm |
Aligos Therapeutics Inc. | ALGS | Vivo Capital VIII LLC Vivo Capital Fund VIII L.P. Vivo Capital Surplus Fund VIII L.P. 10% Owner |
550,000 | $15 | $8,250,000 | 430,372 (Indirect) |
View |
| 2020-10-20 Purchase |
2020-10-20 4:58 pm |
Aligos Therapeutics Inc. | ALGS | Versant Venture Capital VI L.P. Versant Vantage I L.P. 10% Owner |
200,000 | $15 | $3,000,000 | 3,292,339 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2020-12-01 Option Award |
2020-12-03 8:03 pm |
N/A 2030-12-01 |
Aligos Therapeutics Inc. | ALGS | Beigelman Leonid President |
300,000 | $0 | 300,000 (Direct) |
View |
| 2020-12-01 Option Award |
2020-12-03 8:03 pm |
N/A 2030-12-01 |
Aligos Therapeutics Inc. | ALGS | BLATT LAWRENCE Chief Executive Officer |
450,000 | $0 | 450,000 (Direct) |
View |
| 2020-10-20 Conversion |
2020-10-22 4:31 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | Novo Holdings A/S 10% Owner |
4,829,126 | $0 | 2,614,563 (Direct) |
View |
| 2020-10-20 Conversion |
2020-10-22 4:12 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% Owner |
1,906,191 | $0 | 1,906,191 (Direct) |
View |
| 2020-10-20 Conversion |
2020-10-20 5:00 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | Woiwode Thomas Director |
3,092,339 | $0 | 862,444 (Indirect) |
View |
| 2020-10-20 Conversion |
2020-10-20 4:59 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | Vivo Capital VIII LLC Vivo Capital Fund VIII L.P. Vivo Capital Surplus Fund VIII L.P. 10% Owner |
2,997,030 | $0 | 430,372 (Indirect) |
View |
| 2020-10-20 Conversion |
2020-10-20 4:58 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | Versant Venture Capital VI L.P. Versant Vantage I L.P. 10% Owner |
3,092,339 | $0 | 3,292,339 (Direct) |
View |
| 2020-10-20 Conversion |
2020-10-20 4:57 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | Symons Julian A. See Remarks |
18,517 | $0 | 394,064 (Direct) |
View |
| 2020-10-20 Conversion |
2020-10-20 4:56 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | Quan Lucinda Y. See Remarks |
9,258 | $0 | 384,805 (Indirect) |
View |
| 2020-10-20 Conversion |
2020-10-20 4:55 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | Nuechterlein Carole Director |
3,092,340 | $0 | 3,092,340 (Indirect) |
View |
| 2020-10-20 Conversion |
2020-10-20 4:55 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | BLATT LAWRENCE Chief Executive Officer |
273,058 | $0 | 1,255,815 (Indirect) |
View |
| 2020-10-20 Conversion |
2020-10-20 4:53 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | Beigelman Leonid President |
273,057 | $0 | 1,255,650 (Indirect) |
View |
Ownership |
2020-10-15 7:50 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% Owner |
0 | $0 | 1,906,191 (Direct) |
View |
Ownership |
2020-10-15 7:16 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | Novo Holdings A/S 10% Owner |
0 | $0 | 2,414,563 (Direct) |
View |
Ownership |
2020-10-15 5:17 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | Woiwode Thomas Director |
0 | $0 | 3,092,339 (Indirect) |
View |
Ownership |
2020-10-15 5:17 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | Vivo Capital VIII LLC Vivo Capital Fund VIII L.P. Vivo Capital Surplus Fund VIII L.P. 10% Owner |
0 | $0 | 2,997,030 (Indirect) |
View |
Ownership |
2020-10-15 5:16 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | Versant Venture Capital VI L.P. Versant Vantage I L.P. 10% Owner |
0 | $0 | 3,092,339 (Direct) |
View |
Ownership |
2020-10-15 5:15 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | Symons Julian A. See Remarks |
0 | $0 | 453,175 (Direct) |
View |
Ownership |
2020-10-15 5:14 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | Quan Lucinda Y. See Remarks |
0 | $0 | 423,665 (Direct) |
View |
Ownership |
2020-10-15 5:13 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | Nuechterlein Carole Director |
0 | $0 | 3,092,340 (Indirect) |
View |
Ownership |
2020-10-15 5:11 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | Hirth Peter Director |
0 | $0 | 59,549 (Direct) |
View |
Ownership |
2020-10-15 5:11 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | Glaub Kathleen Sereda Director |
0 | $0 | 59,550 (Direct) |
View |
Ownership |
2020-10-15 5:10 pm |
N/A 2030-06-25 |
Aligos Therapeutics Inc. | ALGS | Calhoun Lesley Ann Chief Financial Officer |
0 | $0 | 214,413 (Direct) |
View |
Ownership |
2020-10-15 5:09 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | BLATT LAWRENCE Chief Executive Officer |
0 | $0 | 2,368,752 (Direct) |
View |
Ownership |
2020-10-15 5:08 pm |
N/A N/A |
Aligos Therapeutics Inc. | ALGS | Beigelman Leonid President |
0 | $0 | 1,778,600 (Direct) |
View |